Global Rotavirus Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rotavirus Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the developed world. The vaccines decrease the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
The global Rotavirus Vaccines market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Rotavirus Vaccines include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Rotavirus Vaccines, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Rotavirus Vaccines by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Rotavirus Vaccines market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Rotavirus Vaccines market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
By Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
By Application
Adult
Pediatric
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Rotavirus Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Rotavirus Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rotavirus Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
The global Rotavirus Vaccines market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Rotavirus Vaccines is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Rotavirus Vaccines include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Rotavirus Vaccines, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Rotavirus Vaccines by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Rotavirus Vaccines market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Rotavirus Vaccines market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
By Company
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
By Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
By Application
Adult
Pediatric
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Rotavirus Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Rotavirus Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rotavirus Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.